Publications by authors named "Dale P Conner"

Claim this Profile
S
Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
Qing Liu, Mohammad Absar, Bhawana Saluja, Changning Guo, Badrul Chowdhury, Dale P Conner

AAPS J· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehul U Mehta, Ramana S Uppoor, Dale P Conner, Paul Seo, Jayabharathi Vaidyanathan

Mol Pharm· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.
Ping Ren, Minglei Cui, Om Anand, Li Xia, Zhuojun J Zhao, Dale P Conner

AAPS J· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
Rong Wang, Dale P Conner, Bing V Li

AAPS J· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
Dongmei Lu, Sau L Lee, Robert A Lionberger, Stephanie Choi, Wallace Adams, Dale P Conner

AAPS J· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies.
Nilufer Tampal, Haritha Mandula, Hongling Zhang, Bing V Li, Hoainhon Nguyen, Dale P Conner

AAPS PharmSciTech· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products.
April C Braddy, Barbara M Davit, Ethan M Stier, Dale P Conner

AAPS J· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of imprecision in incurred sample reanalysis for small molecules.
Sriram Subramaniam, Devvrat Patel, Barbara M Davit, Dale P Conner

AAPS J· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common bioanalytical deficiencies with bioequivalence submissions in Abbreviated New Drug Applications.
Leah N Williamson, Dale P Conner, Ethan M Stier, Barbara M Davit

Bioanalysis· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
Paramjeet Kaur, Chandra S Chaurasia, Barbara M Davit, Dale P Conner

J Clin Pharmacol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.
Barbara Davit, April C Braddy, Dale P Conner, Lawrence X Yu

AAPS J· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval.
Bing V Li, Feiyan Jin, Sau L Lee, Tao Bai, Badrul Chowdhury, Dale P Conner

AAPS J· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common reasons for "for-cause" inspections in bioequivalence studies submitted to the Food and Drug Administration.
Bing V Li, Barbara M Davit, Christina H Lee, Santhosh K Pabba, Chitra Mahadevan, Dale P Conner

AAPS J· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.
Anil K Nair, Om Anand, Nam Chun, Dale P Conner, Mehul U Mehta

AAPS J· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
Barbara M Davit, Mei-Ling Chen, Dale P Conner, Sam H Haidar, Stephanie Kim

AAPS J· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations.
Ethan M Stier, Barbara M Davit, Parthapratim Chandaroy, Mei-Ling Chen, Jeanne Fourie-Zirkelbach, Dale P Conner

AAPS J· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
Qing Liu, Barbara M Davit, Svetlana A Cherstniakova, Suman Dandamudi, Johnetta F Walters, Dale P Conner

AAPS J· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.
Wenlei Jiang, Stephanie Kim, Xinyuan Zhang, Robert A Lionberger, Barbara M Davit, Dale P Conner

Int J Pharm· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissolution testing for generic drugs: an FDA perspective.
Om Anand, Lawrence X Yu, Dale P Conner, Barbara M Davit

AAPS J· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
Wallace P Adams, Richard C Ahrens, Mei-Ling Chen, David Christopher, Badrul A Chowdhury, Dale P Conner

J Aerosol Med Pulm Drug Deliv· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Barbara M Davit, Patrick E Nwakama, Gary J Buehler, Dale P Conner, Sam H Haidar

Ann Pharmacother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.
Sau Lawrence Lee, Wallace P Adams, Bing V Li, Dale P Conner, Badrul A Chowdhury

AAPS J· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generic drugs--safe, effective, and affordable.
John R Peters, Dena R Hixon, Dale P Conner, Barbara M Davit, Debra M Catterson

Dermatol Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications.
Barbara M Davit, Dale P Conner, Beth Fabian-Fritsch, Sam H Haidar, Xiaojian Jiang

AAPS J· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs.
Lawrence X Yu, Arthur B Straughn, Patrick J Faustino, Yongsheng Yang, Ameeta Parekh, Dale P Conner

Mol Pharm· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis